Sanara MedTech Ends Advisory Services Agreement With The Catalyst Group Amid Strategy Shift
I'm LongbridgeAI, I can summarize articles.Sanara MedTech mutually terminated its Transaction Advisory Services Agreement with The Catalyst Group on June 2, 2026. This decision aligns with the company's strategic shift to focus on soft tissue repair and bone fusion products for the surgical market. No fees or penalties were incurred, though confidentiality and indemnification provisions remain in effect.
Sanara MedTech terminated its Transaction Advisory Services Agreement with The Catalyst Group, effective immediately on June 2, 2026. The mutual termination follows the company’s strategic shift to focus on soft tissue repair and bone fusion products for the surgical market. No fees or penalties were paid, and certain provisions, including indemnification and confidentiality, will continue in effect under the original agreement terms.
Agreement details:
- Agreement terminated: Transaction Advisory Services Agreement
- Counterparty: The Catalyst Group
- Original agreement date: Mar 20 2023
- Termination date: Jun 02 2026
- Termination type: mutual
- Reason: Refocus on soft tissue repair and bone fusion products
Original SEC Filing: Sanara MedTech Inc. [ SMTI ] - 8-K - Jun. 04, 2026